Camptothecin inhibits the progression of NPC by regulating TGF‑β‑induced activation of the PI3K/AKT signaling pathway

Li,Ben‑Shan; Huang,Ji‑Yi; Guan,Jing; Chen,Long‑Hua

doi:10.3892/ol.2018.8688

Camptothecin inhibits the progression of NPC by regulating TGF‑β‑induced activation of the PI3K/AKT signaling pathway

Authors:
- Ben‑Shan Li
- Ji‑Yi Huang
- Jing Guan
- Long‑Hua Chen
View Affiliations

Affiliations: Department of Radiation Oncology, Nanfang Hospital Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of E.N.T., People's Hospital of Jiangmen, Jiangmen, Guangdong 529000, P.R. China, Department of Oncology, People's Hospital of Jiangmen, Jiangmen, Guangdong 529000, P.R. China
Published online on: May 10, 2018 https://doi.org/10.3892/ol.2018.8688
Pages: 552-558

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is a type of cancer that is characterized by increased invasiveness, metastatic potential and tumor recurrence. Camptothecin has been demonstrated to exhibit anticancer activity. However, the potential underlying molecular mechanisms mediated by camptothecin in NPC cells remain elusive. In the present study, the efficacy of camptothecin for NPC was investigated in vitro and in vivo. Additionally, the potential signaling pathway mediated by camptothecin in NPC cells was also examined. The results indicated that the viability and aggressiveness of NPC cells were suppressed by camptothecin treatment in a dose‑dependent manner. Camptothecin administration downregulated the expression levels of cell‑cycle‑associated proteins including cyclin 1, cyclin‑dependent kinase (CDK)1 and CDK2 in NPC cells. Expression levels of migration‑associated proteins including vimentin, fibronectin and epithelial cadherin were regulated by camptothecin treatment in NPC cells. Additionally, camptothecin inhibited the expression of transforming growth factor‑β (TGF‑β), phosphoinositide 3‑kinase (PI3K) and protein kinase B (AKT), whereas TGF‑β overexpression abrogated camptothecin‑mediated inhibition of PI3K and AKT expression and camptothecin‑mediated inhibition of the viability and aggressiveness of NPC cells. Camptothecin significantly inhibited tumor growth and increased survival times in a mouse model of cancer. In conclusion, these results indicate that camptothecin treatment may inhibit the viability of NPC cells and aggressiveness by regulating the TGF‑β‑induced PI3K/AKT signaling pathways, which in turn may be a potential molecular target for the treatment of NPC.

View Figures

View References

1	Fan W and Du J: Nasal polyps associated with nasopharyngeal carcinoma in child: One case report and review. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 27:273–274. 2013.(In Chinese). PubMed/NCBI
2	Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ and Lee LW: Nasopharyngeal carcinoma: A retrospective review of demographics, treatment and patient outcome in a single centre. Clin Oncol (R Coll Radiol). 25:171–177. 2013. View Article : Google Scholar : PubMed/NCBI
3	Tsang CM and Tsao SW: The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virol Sin. 30:107–121. 2015. View Article : Google Scholar : PubMed/NCBI
4	Dawson CW, Port RJ and Young LS: The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 22:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
5	Strazzulla A, Barreca GS, Giancotti A, Pisani V, Costa C, Zicca E, La Boria A, Roveda L, Liberto MC, Tucci L, et al: Nasopharyngeal carcinoma: Review of the literature with a focus on therapeutical implications. Infez Med. 23:224–229. 2015.PubMed/NCBI
6	Gioacchini FM, Tulli M, Kaleci S, Magliulo G and Re M: Prognostic aspects in the treatment of juvenile nasopharyngeal carcinoma: A systematic review. Eur Arch Otorhinolaryngol. 274:1205–1214. 2017. View Article : Google Scholar : PubMed/NCBI
7	Xiao W, He Z, Xing C, Zhen W, Wang S and Lin H: Clinicopathologic features and treatment of breast metastasis from nasopharyngeal carcinoma: A report of two cases and literature review. Oncol Lett. 10:3675–3681. 2015. View Article : Google Scholar : PubMed/NCBI
8	Setton J, Wolden S, Caria N and Lee N: Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. Head Neck. 34:753–757. 2012. View Article : Google Scholar : PubMed/NCBI
9	Caponigro F, Longo F, Ionna F and Perri F: Treatment approaches to nasopharyngeal carcinoma: A review. Anticancer Drugs. 21:471–477. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yeo CD, Lee SH, Kim JS, Kim SJ, Kim SC, Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, et al: A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer. Cancer Chemother Pharmacol. 72:809–814. 2013. View Article : Google Scholar : PubMed/NCBI
11	Arakawa Y, Ozaki K, Okawa Y and Yamada H: Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines. Oncol Rep. 30:1053–1058. 2013. View Article : Google Scholar : PubMed/NCBI
12	Bertozzi D, Marinello J, Manzo SG, Fornari F, Gramantieri L and Capranico G: The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther. 13:239–248. 2014. View Article : Google Scholar : PubMed/NCBI
13	Veloso A, Biewen B, Paulsen MT, Berg N, de Andrade Lima Carmo L, Prasad J, Bedi K, Magnuson B, Wilson TE and Ljungman M: Genome-wide transcriptional effects of the anti-cancer agent camptothecin. PLoS One. 8:e781902013. View Article : Google Scholar : PubMed/NCBI
14	Lee M, Kim Young S, Kim J, Kim HS, Kim SM and Kim EJ: Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death. Cancer Biol Ther. 14:1007–1015. 2013. View Article : Google Scholar : PubMed/NCBI
15	Sun LC, Luo J, Mackey LV, Fuselier JA and Coy DH: A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/−9. Cancer Lett. 246:157–166. 2007. View Article : Google Scholar : PubMed/NCBI
16	Gaur S, Wang Y, Kretzner L, Chen L, Yen T, Wu X, Yuan YC, Davis M and Yen Y: Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicin. 10:1477–1486. 2014. View Article : Google Scholar
17	Tang Q, Ji F, Guo J, Wang J, Li Y and Bao Y: Directional modification of chrysin for exerting apoptosis and enhancing significantly anti-cancer effects of 10-hydroxy camptothecin. Biomed Pharmacother. 82:693–703. 2016. View Article : Google Scholar : PubMed/NCBI
18	Su H, Zhang P, Cheetham AG, Koo JM, Lin R, Masood A, Schiapparelli P, Quiñones-Hinojosa A and Cui H: Supramolecular crafting of self-assembling camptothecin prodrugs with enhanced efficacy against primary cancer cells. Theranostics. 6:1065–1074. 2016. View Article : Google Scholar : PubMed/NCBI
19	Artyukhin AA: Plastic repair of the deferent duct with a silicone tubular prosthesis under conditions of a chronic experiment on laboratory animals. Bull Exp Biol Med. 144:91–95. 2007.(In English, Russian). View Article : Google Scholar : PubMed/NCBI
20	Renshaw A and Elsheikh TM: A validation study of the Focalpoint GS imaging system for gynecologic cytology screening. Cancer Cytopathol. 121:737–738. 2013. View Article : Google Scholar : PubMed/NCBI
21	Bai FL, Yu YH, Tian H, Ren GP, Wang H, Zhou B, Han XH, Yu QZ and Li DS: Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther. 15:1226–1238. 2014. View Article : Google Scholar : PubMed/NCBI
22	Turki S, Mardassi A, Abouda M, Hachicha A and Ben Jallel W: Orbital metastasis revealing an undifferenciated Carcinoma of nasopharyngeal type: A case report. Tunis Med. 94:148–151. 2016.PubMed/NCBI
23	Genova P, Brunetti F, Bequignon E, Landi F, Lizzi V, Esposito F, Charpy C, Calderaro J, Azoulay D and de'Angelis N: Solitary splenic metastasis from nasopharyngeal carcinoma: A case report and systematic review of the literature. World J Surg Oncol. 14:1842016. View Article : Google Scholar : PubMed/NCBI
24	Ding X, Matsuo K, Xu L, Yang J and Zheng L: Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer. Anticancer Drugs. 26:547–554. 2015. View Article : Google Scholar : PubMed/NCBI
25	Chazin Ede L, Reis Rda R, Junior WT, Moor LF and Vasconcelos TR: An overview on the development of new potentially active camptothecin analogs against cancer. Mini Rev Med Chem. 14:953–962. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zhang LF, Li YH, Xie SH, Ling W, Chen SH, Liu Q, Huang QH and Cao SM: Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: An age-period-cohort analysis. Chin J Cancer. 34:350–357. 2015. View Article : Google Scholar : PubMed/NCBI
27	Liu S, Wang X, Shu J, Zhao Z, Sun Z and Luo B: Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China. J Med Virol. 87:1946–1952. 2015. View Article : Google Scholar : PubMed/NCBI
28	Tian W, Zhu FM, Wang WY, Cai JH, Zhang W, Li LX, Liu KL, Jin HK and Wang F: Sequence-based typing of HLA-A gene in 930 patients with nasopharyngeal carcinoma in Hunan province, southern China. Tissue Antigens. 86:15–20. 2015. View Article : Google Scholar : PubMed/NCBI
29	Hamilton G, Klameth L, Rath B and Thalhammer T: Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines. Molecules. 19:2077–2088. 2014. View Article : Google Scholar : PubMed/NCBI
30	Mollica A, Stefanucci A, Feliciani F, Cacciatore I, Cornacchia C and Pinnen F: Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer. Curr Drug Deliv. 9:122–131. 2012. View Article : Google Scholar : PubMed/NCBI
31	Liu Z, Zheng Q, Chen W, Wu M, Pan G, Yang K, Li X, Man S, Teng Y, Yu P and Gao W: Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways. Eur J Med Chem. 125:760–769. 2017. View Article : Google Scholar : PubMed/NCBI
32	Park ES, Kang SI, Yoo KD, Lee MY, Yoo HS, Hong JT, Shin HS, Kim B and Yun YP: Camptothecin inhibits platelet-derived growth factor-BB-induced proliferation of rat aortic vascular smooth muscle cells through inhibition of PI3K/Akt signaling pathway. Exp Cell Res. 319:982–991. 2013. View Article : Google Scholar : PubMed/NCBI
33	Jayasooriya RG, Park SR, Choi YH, Hyun JW, Chang WY and Kim GY: Camptothecin suppresses expression of matrix metalloproteinase-9 and vascular endothelial growth factor in DU145 cells through PI3K/Akt-mediated inhibition of NF-κB activity and Nrf2-dependent induction of HO-1 expression. Environ Toxicol Pharmacol. 39:1189–1198. 2015. View Article : Google Scholar : PubMed/NCBI